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Pharmacologic restoration of DF508 CFTR-mediated chloride transport can be restored (abstract; Rubenstein et al,
current. Cystic fibrosis (CF) is an autosomal inherited disorder Pediatr Pulmon S17:211, 1998) [7]. Thus, therapies di-
caused by over 800 different mutations in the CFTR gene. The rected at aberrant CFTR protein trafficking would bemost common mutation, DF508, causes a trafficking arrest in
desirable.the endoplasmic reticulum and the CFTR protein is degraded.
Restoration of CFTR trafficking in vitro restores cAMP-medi-
ated chloride transport at the cell surface. The hypothesis of
TRAFFICKING DEFECTS IN CFTR CANthis discussion is that the short chain fatty acids, butyrate and
4-phenylbutyrate, up-regulate mature CFTR at the plasma BE CORRECTED
membrane. Evidence that these compounds regulate CFTR
Cystic fibrosis transmembrane conductance regulatorproduction and maturation in part through effects on molecular
(CFTR) biosynthesis is a balance between normal pro-chaperones in CF cells in culture is discussed. The oral drug,
4-phenylbutyrate, was tested in a Phase I clinical trial in CF cessing and proteolysis (Fig. 1A). Membrane glycopro-
subjects and further trials are underway. Other new therapeutic teins typically assemble in the endoplasmic reticulum
approaches directed at different classes of mutations in CFTR where they are core-glycosylated, then move to the Golgiare also discussed. Chemical and pharmacologic agents that
apparatus to complete glycosylation, and then arrive atregulate endogenous gene expression at different steps in the
the plasma membrane, via vesicles that bud off frombiosynthetic processing pathway of a membrane glycoprotein
will be needed to comprehensively treat a complex inherited the Golgi. In vitro studies in heterologous cell culture
disorder like cystic fibrosis. systems suggest that at best, only 25% of newly synthe-
sized wild-type CFTR escapes the endoplasmic reticulum
to be glycosylated in the Golgi and inserted onto the
Despite 10 years of intensive investigation of the ge- plasma membrane attaining a final mobility of about 180
netics, pathophysiology, and clinical phenotypes of cystic kDa on SDS-PAGE [8–10]. The other 75% of apparently
fibrosis (CF), the disease remains one of the most com- normal protein is ubiquitinated and degraded [11].
mon lethal inherited autosomal recessive disorders in DF508 is even less successful than wild type CFTR.
the Caucasian population worldwide. The gene encodes
DF508 CFTR fails to progress to the Golgi apparatus and
the cystic fibrosis transmembrane conductance regulator the cell surface (Fig. 1C), and runs as a core-glycosylated
(CFTR) protein, a 1480 amino acid, glycosylated, mem- protein of approximately 150 kD on an SDS-PAGE gel.
brane glycoprotein that functions as a cAMP-regulated
Failure to pass through the Golgi can be recognized by
chloride channel in exocrine glands or secretory epithelia
failure to become fully glycosylated and attain a mobility[1]. Seventy percent of patients carry one or two copies of
of 170 to 180 kD on an SDS-PAGE gel (Band C, Fig.the DF508 mutation, and over 800 additional mutations
1A). The deletion of the phenylalanine at position 508account for the remaining disease-causing alleles. The
is hypothesized to result in misfolding of the nascent
DF508 allele is a trafficking mutation, meaning that the
chain as it emerges from the ribosome, where it is recog-mutant protein is blocked from maturation in the endo-
nized by the molecular chaperones that target it for earlyplasmic reticulum and is targeted for premature proteol-
proteolysis. There is much evidence for misfolding ofysis [2]. Although chloride channel conductance is af-
CFTR: a reduced stability of DF508 at the cell membranefected to some degree [3–6], if the DF508 protein is
[12], slightly altered circular dichroism spectra of a pep-redirected to the cell surface, cAMP-mediated chloride
tide containing this site [13], restoration of processing
by incubation of cells at temperatures between 25 and
Key words: cystic fibrosis, protein trafficking, butyrates. 298C [7, 8], and restoration of processing by chemical
chaperones [9]. Similar misfolding and impairment ofÓ 2000 by the International Society of Nephrology
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protein trafficking is seen for mutations in the alpha1- up-regulate CFTR expression. However, it is not yet
clear that up-regulation of DF508 mRNA expressionantitrypsin gene, aquaporin-2 in nephrogenic diabetes
insipidus [14], Tay-Sachs disease, familial hypercholes- would be sufficient to overwhelm the cellular stress mech-
anisms leading to premature destruction, or whether ad-terolemia, and for accumulation of insoluble protein ag-
gregates in Alzheimer’s and prion-associated disorders. ditional genes in the trafficking pathway must be modu-
lated. Low molecular weight fatty acids, such as butyrateIt was initially hypothesized that by blocking ER-asso-
ciated proteolytic degradation, a greater amount of ma- and phenylbutyrate, restore DF508 to the cell surface
at 378C in culture [19]. Treatment of CF cell culturesture DF508-CFTR would be produced. However, inhibi-
tion of CFTR proteolysis by lactacystin or ALLN does expressing endogenous levels of DF508 with sodium bu-
tyrate or sodium 4-phenylbutyrate at nontoxic concen-not force CFTR through the normal pathway [11]. Thus,
trations increases total CFTR protein and normal CFTRtherapeutic interventions designed to restore normal
processing and leads to cAMP-mediated chloride con-trafficking must be targeted proximal to ubiquitination
duction at the cell surface [20]. Butyrate-mediated effectsand proteolysis in the endoplasmic reticulum. Detailed
on CFTR may be at least twofold—an induction ofstudies of nascent CFTR polypeptide chain interactions
CFTR expression and modulation of molecular chaper-with molecular chaperones would be informative.
one expression.
Wild-type CFTR “folding” and progression to a prote-
TEMPERATURE–SENSITIVE ase-resistant state is assisted by endoplasmic reticulum
CFTR TRAFFICKING (ER)-associated chaperone proteins. Heat shock protein
Growth of DF508 CFTR-expressing cells at reduced 70 (Hsp70) [21] and calnexin [22], but not BiP and Grp94
temperature (25 to 308C) dramatically corrects the traf- [2] appear to associate with CFTR transiently. Prolonga-
ficking defect and restores cAMP-mediated chloride tion of the complex of Hsp70 and DF508 CFTR has been
transport at the plasma membrane [12] This effect can observed, suggesting that Hsp70 may recognize CFTR
be mimicked at 378C by chemical “chaperones” such as for early removal. Hsc70, a member of the Hsp70 family,
glycerol, dimethylsulfoxide (DMSO), trimethylamine-N- is constitutively expressed, and has also been implicated
oxide (TMAO), and deuterated water [15]. Extremely as a signal for removal to the proteolytic pathway [23].
high concentrations are required, and thus, direct in vivo Hdj-2/Hsc70 complexes associate with wild-type and
application is impractical. High throughput screening DF508 CFTR [24]. Preliminary data implicate a phenyl-
and combinatorial chemistry approaches may accelerate butyrate-mediated specific reduction in Hsc70 to explain
the identification of a clinically applicable compound. the shift of mutant CFTR onto the trafficking pathway
Studies of organ-specific adaptations to stress may also [8]. Because DF508 retains some chloride channel activ-
ity [4, 5], modulation of these chaperone associationsprovide clues to alternative chemical chaperones. The
or additions of a chemical chaperone are reasonablekidney has adapted local environments to protect itself
therapeutic avenues.against hyperosmotic stress. By accumulation of “cellu-
In a randomized, double-blind, placebo-controlledlar osmolytes,” urea-mediated protein denaturation is
trial in CF patients homozygous for DF508, one week ofavoided. TMAO is synthesized by the renal medulla
phenylbutyrate, at 20 g/day, was associated with a modestto protect the intracellular environment against urea.
induction of chloride transport based on nasal potentialCarbohydrates or myoinositol, free amino acids such as
difference measurements [25]. Importantly, no safety is-glycine or alanine, and methylamines such as betaine,
sues arose in the CF trial, suggesting that a moderate,are either transported in or synthesized by other tissues
but selective, reduction in Hsc70 was not associated within hyperosmotic stress [15]. It might be possible to adapt
widespread disruption of the quality control mechanismthese principles locally within the lung, liver, or intestine.
for folding or degrading proteins. 4-Phenylbutyrate (Bu-
phenyl) is a newly approved drug for the rare inherited
BUTYRATE-MEDIATED CORRECTION OF urea cycle disorders, where it functions to provide an
CFTR PROCESSING alternative vehicle for waste nitrogen excretion by conju-
Gene expression (fetal hemoglobin is one example) gation with glutamine. 4-Phenylbutyrate is under study in
can be modulated by small chain fatty acids such as the hemoglobinopathies [26, 27], adrenoleukodystrophy
butyric acid and its derivatives. The effect can be repro- [28], and in cancer trials [29]. Dose escalation and phar-
duced by inhibitors of histone deacetylase [16]. Genes macokinetic studies are continuing in adults with CF.
active during fetal development are usually silenced in There may be other pharmaceuticals capable of regu-
postnatal life. Inhibition of histone deacetylase de- lating the molecular chaperones. Deoxyspergualin (DSG)
represses fetal hemoglobin and many other genes. Given is a stable synthetic analog of the natural product spergu-
that CFTR is also more abundant in fetal than adult alin, and is known to compete effectively for binding with
Hsp70 and Hsp90. DSG has potent immunosuppressivetissue [17, 18], it is not surprising that the butyrates can
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Fig. 1. CFTR biogenesis and trafficking. (A) Normal or wild-type CFTR biosynthesis is a balance between early proteolysis from the endoplasmic
reticulum (75%, bands A and B on SDS-PAGE of immunoprecipitated and phosphorylated CFTR) and processing (25%, bands A, B, and C on
SDS-PAGE). (B) Class I mutations, such as W1282X, produce an early stop codon, unstable mRNA, and absence of CFTR protein. (C) Class II
mutations are trafficking mutations. The DF508 example results in early degradation (99%, bands A and B only). (D) Class III mutations produce
fully processed CFTR resident on the plasma membrane (bands A, B, C). (E) Class IV mutations produce fully processed protein that trafficks
normally (bands A, B, C). (F ) Class V mutations involve promoter and splicing abnormalities and typically result in very low levels of normal
CFTR (bands A, B, C). Publication of this figure in color was provided by a grant from Ucyclyd Pharmaceuticals, Inc., Phoenix, AZ, USA.
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activity mediated in part through interactions with Hsc70 mutation. G551D is a Class III mutation that is synthe-
and Hsp90. One research group has studied DSG and sized, resides in the plasma membrane, but is not acti-
reported appearance of functional cAMP-stimulated vated with isoproterenol (Fig. 1D). The ability of gen-
CFTR chloride channel activity at the cell surface in istein to activate G551D in the intestine of the G551D
both immortalized human CF airway and biliary epithe- CF mouse has also been observed [40].
lial cells [30].
NEW APPROACHES TO CLASS I DEFECTS
CFTR CHLORIDE CHANNEL ACTIVATORS IN CFTR
The previous discussion has been confined to modula- Pharmacologic correction of CFTR defects must take
tors of trafficking; however, the DF508 CFTR is still less under consideration the full range of observed abnormal-
active as a chloride channel than normal CFTR. Both ities. Beginning with the Class I defects, it is clear that a
trafficking and chloride channel properties appear, at variety of approaches will be required. Class I mutations
least in vitro, to be favorably altered by CPX (8-cyclo- generate premature stop codons that result in truncated
pentyl-1,3-dipropylxanthine) [31, 32], an adenosine re- mRNA transcripts that are inherently unstable and fail
ceptor antagonist that directly binds to DF508 CFTR to be translated into proteins (Fig. 1B). The efficiency
in a region that structurally resembles the adenosine of translation termination tends to vary as a function of
receptor. A Phase I dose escalation and safety trial was the surrounding amino acid, that is, context-sensitivity.
recently completed in CF, and a Phase II trial is in prog- Certain aminoglycosides, such as G418 and gentamicin,
ress. Other analogs are undergoing laboratory assess- suppress premature chain termination and restore read-
ment and look very promising [33]. through to full length CFTR [41]. W1282X and R553X
Genistein, a member of the flavonoid class of mole- can be rescued in vitro. Given that W1282X mRNA is
cules, activates CFTR through a highly debated mecha- unusually stable in certain patients [42], topical, inhaled,
nism [34]. Genistein is a tyrosine kinase inhibitor; how- and intravenous gentamicin is under study in the U.S.
ever, not all tyrosine kinase inhibitors activate CFTR. and Israel (abstract; Wilschanski et al, Pediatr Pulmon
Genistein does not increase cAMP levels [35], and more S17:168, 1998) [43]. Preliminary data from these small
recent data implicate direct binding to the nucleotide clinical trials is encouraging. Modest nasal potential dif-
binding domains of phosphorylated CFTR [36]. Gen- ference responses to isoproterenol in CF patients homo-
istein and related flavonoids are ubiquitous in the human zygous for stop codon mutations have been reported
diet in plant foods such as soybeans and legumes. Their (abstract; Wilshanski et al; ibid).
pharmacology and toxicology have been intensely inves-
tigated. It is known that flavonoid intake from a normal
CLASS III REGULATION OR ACTIVATIONdiet can result in a blood concentration of 1 to 2 mmol/L
MUTATIONS ARE DIFFICULT TO REPAIRin humans [37]. Small pilot studies of genistein and re-
lated flavonoids in nasal epithelia of normal volunteers Class III CFTR mutants exhibit reduced responses to
demonstrated augmentation of the nasal potential differ- regulatory molecules (Fig. 1D). G551D is a common
ence response to isoproterenol [38]. Class III mutation that does not conduct chloride in
Genistein and other flavonoid compounds effectively response to elevated cAMP, but is trafficked to the
activate chloride conduction through the DF508 CFTR plasma membrane. Other Class III mutations can inter-
[39], although they do not appear to favorably restore fere with nucleotide binding and hydrolysis, and disrupt
trafficking. One group has demonstrated that pretreat- CFTR function to a variable degree. These mutants sus-
ment of CF cells with 4-phenylbutyrate or low tempera- tain a reduced response to adenosine 59-triphosphate
ture to induce DF508 trafficking to the plasma mem- (ATP); examples include S1255P, G551S, G1244E, and
brane, allowed genistein to activate chloride transport G1349D. It may be possible to find molecules that alter
(abstract; Fischer et al, Pediatr Pulmon S17:239, 1998). the interaction of the CFTR domains with ATP and
Results from a pilot clinical trial of topical genistein in restore activity to these mutants.
CF nasal epithelia alone or in combination with isopro-
terenol demonstrated a modest hyperpolarization in the
CLASS IV CONDUCTION MUTATIONS AREnasal potential difference response to low chloride in
ASSOCIATED WITH A MILD PHENOTYPEnormal volunteers, but not in CF patients homozygous
Class IV mutants such as R117H, G314E, R334 W, andfor DF508. Restoration of DF508 CFTR trafficking will
R347P are associated with normal trafficking, proteinbe necessary for the flavonoids to be effective (abstract;
kinase A (PKA)-dependent response to phosphoryla-Gondor et al, Pediatr Pulmon S17:253, 1998). On the
tion, and ATP binding. Defects instead lie in chlorideother hand, genistein alone induced a small chloride
response in CF patients carrying one copy of the G551D conductance or channel gating (Fig. 1E). The mutations
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tend to occur within the regions of CFTR that form the SUMMARY
chloride pore. R347P affects the rate of chloride flow, Chemical and pharmacologic mediators of protein
whereas R117H and P574H reduce the channel open trafficking are needed in CF and other diseases caused
time. The latter mutation is sometimes placed in Class by trafficking mutations. Drugs that regulate endogenous
II because of a reduced efficiency of processing. The gene expression may also be useful in the induction of
milder clinical phenotypes observed in patients with a alternative enzymatic pathways in diseases such as CF,
Class IV mutation suggest that treatments aimed at pro- the hemoglobinopathies, adrenoleukodystrophy, and
moting CFTR trafficking and activating or increasing cancer. CF is one example where multiple approaches
will be needed due to the spectrum of abnormalitieschloride conductance would tend to support a milder
observed. Certainly, genotyping will become clinicallycourse.
indicated in all the inherited disorders and thus mayOne drug that may be capable of stimulating Class IV
specifically direct therapeutic intervention.CFTR chloride conduction is an approved phosphodies-
terase inhibitor that sustains elevated cAMP. Milrinone
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